105 174

Cited 0 times in

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer

DC Field Value Language
dc.contributor.author김건민-
dc.contributor.author김민환-
dc.contributor.author김승일-
dc.contributor.author김지예-
dc.contributor.author김지형-
dc.contributor.author박병우-
dc.contributor.author박세호-
dc.contributor.author박형석-
dc.contributor.author정준-
dc.contributor.author지정환-
dc.contributor.author김슬기-
dc.contributor.author손주혁-
dc.date.accessioned2024-01-03T00:24:19Z-
dc.date.available2024-01-03T00:24:19Z-
dc.date.issued2023-10-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197256-
dc.description.abstractPurpose: Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)-positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia. Materials and methods: Patients with HR-positive, human epidermal growth factor receptor 2-negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups. Results: During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality. Conclusion: Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use-
dc.subject.MESHBreast Neoplasms* / pathology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHNeutropenia* / chemically induced-
dc.subject.MESHReceptor, ErbB-2 / metabolism-
dc.titleEfficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeul-Gi Kim-
dc.contributor.googleauthorMin Hwan Kim-
dc.contributor.googleauthorSejung Park-
dc.contributor.googleauthorGun Min Kim-
dc.contributor.googleauthorJee Hung Kim-
dc.contributor.googleauthorJee Ye Kim-
dc.contributor.googleauthorHyung Seok Park-
dc.contributor.googleauthorSeho Park-
dc.contributor.googleauthorByeong Woo Park-
dc.contributor.googleauthorSeung Il Kim-
dc.contributor.googleauthorJung Hwan Ji-
dc.contributor.googleauthorJoon Jeong-
dc.contributor.googleauthorKabsoo Shin-
dc.contributor.googleauthorJieun Lee-
dc.contributor.googleauthorHyung-Don Kim-
dc.contributor.googleauthorKyung Hae Jung-
dc.contributor.googleauthorJoohyuk Sohn-
dc.identifier.doi10.4143/crt.2022.1543-
dc.contributor.localIdA00287-
dc.contributor.localIdA00482-
dc.contributor.localIdA00658-
dc.contributor.localIdA00984-
dc.contributor.localIdA00999-
dc.contributor.localIdA01475-
dc.contributor.localIdA01524-
dc.contributor.localIdA01753-
dc.contributor.localIdA03727-
dc.contributor.localIdA06110-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid37054718-
dc.subject.keywordAfebrile neutropenia-
dc.subject.keywordLimited dose modification-
dc.subject.keywordMetastatic breast cancer-
dc.subject.keywordPalbociclib-
dc.subject.keywordProgression-free survival-
dc.contributor.alternativeNameKim, Gun Min-
dc.contributor.affiliatedAuthor김건민-
dc.contributor.affiliatedAuthor김민환-
dc.contributor.affiliatedAuthor김승일-
dc.contributor.affiliatedAuthor김지예-
dc.contributor.affiliatedAuthor김지형-
dc.contributor.affiliatedAuthor박병우-
dc.contributor.affiliatedAuthor박세호-
dc.contributor.affiliatedAuthor박형석-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor지정환-
dc.citation.volume55-
dc.citation.number4-
dc.citation.startPage1198-
dc.citation.endPage1209-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.55(4) : 1198-1209, 2023-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.